An LNP-CRISPR gene editing drug demonstrates efficacy and safety in patients with hereditary angioedema following in vivo administration. Pardi N, Ivics Z. J Allergy Clin Immunol 2024;154:272-274.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Pardi N, Ivics Z. An LNP-CRISPR gene editing drug demonstrates efficacy and safety in patients with hereditary angioedema following in vivo administration. J Allergy Clin Immunol 2024;154:272-274.
PMID: 38925443